Piper Sandler Upgrades Globus Medical to Overweight, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has upgraded Globus Medical (NYSE:GMED) from Neutral to Overweight and raised the price target from $60 to $80.
May 20, 2024 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has upgraded Globus Medical from Neutral to Overweight and increased the price target from $60 to $80, indicating a positive outlook for the stock.
The upgrade from Neutral to Overweight by Piper Sandler suggests increased confidence in Globus Medical's future performance. The raised price target from $60 to $80 indicates a significant potential upside, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100